Compare Pfizer Inc (PFE) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Under Armour Inc Class A — how do they compare? Pfizer Inc trades at $24.92 (market cap $142.14B), while Under Armour Inc Class A trades at $7.2 (market cap $3.11B). The key difference: Pfizer Inc is far larger — about 45.7× Under Armour Inc Class A's market cap, and Pfizer Inc pays a 6.9% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| PFE | UAA | |
|---|---|---|
Market Cap | $142.14B | $3.11B |
Volume | 29,869,932 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $28.56 | $8.14 |
52-Week Low | $23.29 | $4.17 |
Enterprise Value | $192.80B | $4.74B |
Dividend Yield | 6.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.
Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.
Under Armour (UAA) trades at $7.37, down 0.81% today, with mixed signals: technicals are bullish on moving averages but RSI suggests overbought conditions. Fundamentally, the company reported a net loss of $201.27M in 2025 with negative margins, though recent quarters showed earnings beats. Cash flow trends are volatile, with 2025 net cash outflow of $361.87M. News highlights include a new Dodge collaboration and upcoming Q1 2027 earnings on August 7, 2026.
The outlook remains challenging due to weak North American sales and margin pressure, but international growth offers some offset. Analyst consensus is cautious with a $5.96 price target below current levels. Key risks include consumer spending softness and high debt. For investors, stabilization in earnings and cost control are critical for a turnaround, though near-term headwinds persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
